Opinion|Videos|May 7, 2024
The Future of Graft Versus Host Disease
Author(s)Yi-Bin Chen, MD
In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical trials aimed at replacing steroids as the first-line treatment approach.
Advertisement
Episodes in this series
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5